Evidence map›Paper›PMID 41614826›Full record

ArticleCurrent issues in molecular biology2025

Potential Use of VYN202, a Novel Small Molecular Bromodomain and Extra-Terminal Inhibitor, in Mitigating Secondhand Smoke (SHS)-Induced Pulmonary Inflammation.

Katelyn A Sturgis, Benjamin D Davidson, Andrew W Richardson, Olivia Hiatt, Blake C Edwards, Ethan P Evans, Carrleigh Campbell, Jack H Radford, Juan A Arroyo, Benjamin T Bikman and 1 more

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katelyn A SturgisDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Benjamin D DavidsonDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0009-0003-5686-4940
Andrew W RichardsonDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Olivia HiattDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Blake C EdwardsDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Ethan P EvansDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0009-0008-2836-9682
Carrleigh CampbellDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Jack H RadfordDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Juan A ArroyoDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0000-0002-8818-8786
Benjamin T BikmanDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Paul R ReynoldsDepartment of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.ORCID 0000-0002-0931-3025

Funding

Flight Attendant Medical Research Institute CIA2300003
6 · The paper itself

Abstract

Inflammation underpins pulmonary disease progression during tobacco smoke exposure, which may culminate in irreversible pulmonary disease. While primary smoke poses a notable risk, nearly half of the US population is also susceptible due to frequent exposure to secondhand smoke (SHS). In the present study, we assessed the potential role of VYN202, a novel small molecular bromodomain and extra-terminal inhibitor, as a possible means of attenuating SHS-mediated inflammation. We exposed wild-type mice to an acute time course of room air (RA), SHS via a nose-only delivery system (Scireq Scientific, Montreal, Canada), or to both SHS and 10 mg/kg VYN202 (efficacious dose from prior inflammatory models) via oral gavage three times a week. Specific smoke exposure delivery to mice involved SHS from two cigarettes over 10 min, equilibration in room air for 10 min, followed by exposure to SHS from one cigarette for an additional 10 min, for a total SHS exposure of 20 min per day, five days a week for 30 days. We evaluated leukocyte abundance and the secretion of inflammatory mediators in bronchoalveolar lavage fluid (BALF). We also assessed general morphology via histology staining and the activation of receptor tyrosine kinase (RTK) family members. While standard hematoxylin and eosin (H&E) staining resulted in unchanged morphology, SHS-mediated increases in BALF protein abundance, total cellularity, and percent PMNs were attenuated with concomitant administration of VYN202. We also discovered SHS-induced activation of RTKs that were pro-inflammatory (JAK1, JAK3, ABL1, and ACK1), as well as RTKs related to endothelial and vascular remodeling (VEGFR3, VEGFR2, EphB4, EphB6, and FAK). Furthermore, inflammatory cytokines including GCSF, IFN-γ, IL-12p70, IL-17A, LIX, and TNF-α were all augmented by SHS exposure. Despite SHS exposure, each of these RTKs and cytokines/chemokines was significantly attenuated by VYN202. In summary, inflammatory responses induced by SHS exposure were mitigated by VYN202. These data reveal fascinating potential for the utility of VYN202 in lessening smoke-induced pulmonary exacerbations.

Indexed as

inflammationlungsecondhand smoketobacco

Identifiers

PMID41614826
PMCPMC12731855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.